一种新的假说：伊马替尼对白血病干细胞的影响方式与其对所有其他白血病细胞的影响方式相同。 - Suppr

Suppr

超能文献

A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells.

作者信息

Tomasetti C

出版信息

Blood Cancer J. 2011 May;1(5):e19. doi: 10.1038/bcj.2011.17. Epub 2011 May 13.

DOI:10.1038/bcj.2011.17

PMID:22829154

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3255261/

Abstract

摘要

相似文献

A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells.

Blood Cancer J. 2011 May;1(5):e19. doi: 10.1038/bcj.2011.17. Epub 2011 May 13.

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.

PLoS Comput Biol. 2009 Sep;5(9):e1000503. doi: 10.1371/journal.pcbi.1000503. Epub 2009 Sep 11.

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.

Blood. 2011 Aug 11;118(6):1622-31. doi: 10.1182/blood-2011-02-339267. Epub 2011 Jun 8.

Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.

Cancer Res. 2015 Oct 1;75(19):4053-62. doi: 10.1158/0008-5472.CAN-15-0611. Epub 2015 Sep 10.

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

PLoS One. 2011;6(7):e21924. doi: 10.1371/journal.pone.0021924. Epub 2011 Jul 18.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5. doi: 10.1073/pnas.0606509103. Epub 2006 Oct 31.

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Clin Cancer Res. 2011 Nov 1;17(21):6812-21. doi: 10.1158/1078-0432.CCR-11-0396. Epub 2011 Sep 8.

Chronic myeloid leukemia blast crisis arises from progenitors.

Stem Cells. 2007 May;25(5):1114-8. doi: 10.1634/stemcells.2006-0638. Epub 2007 Jan 11.

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.

Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.

Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.

Leukemia. 2013 Aug;27(8):1650-8. doi: 10.1038/leu.2013.60. Epub 2013 Feb 25.

引用本文的文献

One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.

Hypoxia (Auckl). 2014 Jan 21;2:1-10. doi: 10.2147/HP.S51812. eCollection 2014.

A Review of Mathematical Models for Leukemia and Lymphoma.

Drug Discov Today Dis Models. 2015 Summer;16:1-6. doi: 10.1016/j.ddmod.2014.10.002. Epub 2014 Nov 29.

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.

F1000Res. 2013 Jul 9;2:152. doi: 10.12688/f1000research.2-152.v1. eCollection 2013.

Standing genetic variation and the evolution of drug resistance in HIV.

PLoS Comput Biol. 2012;8(6):e1002527. doi: 10.1371/journal.pcbi.1002527. Epub 2012 Jun 7.

The dynamics of drug resistance: a mathematical perspective.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):90-7. doi: 10.1016/j.drup.2012.01.003. Epub 2012 Mar 3.

本文引用的文献

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.

Insights into the stem cells of chronic myeloid leukemia.

Leukemia. 2010 Nov;24(11):1823-33. doi: 10.1038/leu.2010.159. Epub 2010 Sep 23.

Role of symmetric and asymmetric division of stem cells in developing drug resistance.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16766-71. doi: 10.1073/pnas.1007726107. Epub 2010 Sep 8.

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Leukemia. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12.

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Cancer. 2008 Feb 15;112(4):837-45. doi: 10.1002/cncr.23238.

Dynamics of chronic myeloid leukaemia.

Nature. 2005 Jun 30;435(7046):1267-70. doi: 10.1038/nature03669.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457.

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Blood. 2002 Jan 1;99(1):319-25. doi: 10.1182/blood.v99.1.319.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验